REG - IXICO plc - Trading Update

IXICOAnnouncement

10/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230510:nRSJ7911Ya&default-theme=true

RNS Number : 7911Y  IXICO plc  10 May 2023

10 May 2023

IXICO plc

("IXICO" or the "Company")

 

Half-year Trading update

 

First six months of trading in line with expectations and confirmation of 2023
market guidance

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, today provides a trading
update ahead of its interim results for the six months ended 31 March 2023.

 

Key metrics:

 

· Revenues expected to be £3.2m for six months to 31 March 2023 (H1
2022: £3.9m);

· Contracted order book of £13.3m as at 31 March 2023 (H1
2022: £12.6m);

· Strong cash balance at 31 March 2023 of £5.0m (H1 2022: £5.9m), debt
free, and operating cash generative;

· Loss before interest, tax, depreciation, and amortisation to 31 March
2023 expected to be £0.6m (H1 2022:  £0.5m profit).

 

The Board reaffirms market guidance for the full year and return to revenue
growth in 2024. 2023 will be the final period to reflect the negative impact
of the large HD-trial cessations announced on 23 March 2021 and on 20 January
2022, with revenues now increasingly driven by recently contracted trials
across a broader range of therapeutic areas.

 

IXICO continues to invest in creating a medical imaging company with leading
advanced AI analysis capabilities, delivered through a next generation imaging
platform designed to address the growing demand for neuroimaging.

 

The Company's first half results will be released on 23 May 2023.

 

Giulio Cerroni, CEO of IXICO, said: "The re-building of our order book is a
priority as we look to benefit from investments we are making in our
commercial capabilities to support our pipeline of opportunities and address
the demand for our specialist AI neuroimaging analytical services.

 

The combination of our diversified order book, near term opportunities and a
commitment to being at the forefront of AI based imaging biomarker analysis,
mean we are well placed to deliver double digit revenue growth across the
second half of FY-2023 as compared to the first half, providing the foundation
for further growth across 2024 and beyond."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 (MAR).

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning Ai data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSSASWUEDSEII